Regenerative Medicine Market by Type [Cell-Based Immunotherapy & Cell Therapy (Allogeneic & Autologous Products), Tissue Engineering, Gene Therapy], Applications (Wounds & Dermal, Musculoskeletal, Oncology), Region - Global Forecast to 2024

再生医療の世界市場予測(~2024年)

◆タイトル:Regenerative Medicine Market by Type [Cell-Based Immunotherapy & Cell Therapy (Allogeneic & Autologous Products), Tissue Engineering, Gene Therapy], Applications (Wounds & Dermal, Musculoskeletal, Oncology), Region - Global Forecast to 2024
◆商品コード:BT-4419
◆調査・発行会社:MarketsandMarkets
◆発行日:2019年3月29日
◆ページ数:108
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:バイオテクノロジー
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD5,650 ⇒換算¥610,200見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥718,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥880,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

再生医療の世界市場は、2019年の133億米ドルから2024年には387億米ドルに達し、この期間中23.8%の年平均成長率で成長すると予測されています。この市場の成長を促す要因として、がん発生率の上昇、高齢者人口の増加、CAR-T細胞療法などの再生医療の技術的シフト、ヘルスケアセクターの成長や可処分所得の上昇につながる経済が考えられます。当調査レポートでは、再生医療の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、種類別(細胞ベースの免疫療法・細胞療法、組織工学、遺伝子治療)分析、用途別(創傷・皮膚損傷、筋骨格系疾患、腫瘍)分析、再生医療の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

・イントロダクション
・エグゼクティブサマリー
・再生医療の世界市場:市場インサイト
・再生医療の世界市場:市場概観/市場動向
・再生医療の世界市場:市場シェア分析
・再生医療の世界市場:種類別(細胞ベースの免疫療法・細胞療法、組織工学、遺伝子治療)分析/市場規模
・再生医療の世界市場:用途別(創傷・皮膚損傷、筋骨格系疾患、腫瘍)分析/市場規模
・再生医療のアジア市場規模予測
・再生医療のヨーロッパ市場規模予測
・再生医療のアメリカ市場規模予測
・再生医療の世界市場動向
・再生医療の世界市場:競争状況
・再生医療の世界市場:関連企業分析
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

“Regenerative medicine market to register a CAGR of 23.8% from 2019 to 2024”The regenerative medicine market is projected to reach USD 38.7 billion by 2024 from USD 13.3 billion in 2019, at a CAGR of 23.8% during the forecast period. The rising global incidence of cancer, increasing global aging population, and technological shifts in regenerative medicine such as CAR-T cell therapy are factors expected to drive market growth during the forecast period. Economies with growing healthcare sector and high disposable income are also expected to provide opportunities for the growth of the market.

“Cell-based immunotherapy & cell therapy products likely to grow at a CAGR during the forecast period”
By type, the regenerative medicine market is segmented into cell-based immunotherapy & cell therapy products, tissue-engineered products, and gene therapy products. The cell-based immunotherapy & cell therapy products segment dominates this market in 2019 and is the fastest growing segment due to increasing launches of novel cell therapies, increasing demand for novel treatments with less side effects for the treatment of cancer are the major factors driving the growth of this market segment.

“Musculoskeletal Disorders application segment accounted for the largest share of the regenerative medicine market in 2019 and oncology segment expected to achive highest growth rate in the future”
By application, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, diabetes, and other applications. Musculoskeletal disorder applications segment likely to account for the largest share of this market and oncology is likely to register highest CAGR during the forecast period. The surging incidence rate of orthopaedic diseases & injuries, and rising geriatric population, are the key drivers for the growth of this market segment.
“North America is expected to attain fastest growth rate and dominated the regenerative medicine market in 2019”
North America, which includes the US, & Canada, accounted for the largest share of the regenerative medicine market. The large share of this market segment can be attributed to the increasing incidence of chronic wounds, diabetes, leukemia and musculoskeletal diseases in this region.

Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 (20%) , Tier 2 (45%), and Tier 3 (35%)
• By Designation: C-level (30%), Director-level (20%), and Others (50%)
• By Region: North America (35%), Europe (24%), Asia (25%), and RoW (16%)

The major players in this market are Kite Pharma (US), Novartis (Switzerland), Vericel Corporation (US), Integra LifeSciences (US), Wright Medical (US), MiMedx (US), Osiris Therapeutics (US), Stryker Corporation (US), and Spark Therapeutics (US). Product launches and acquisitions are the key growth strategies followed by most players in this market.

Research Coverage
This report studies the regenerative medicine market based on type, and region. The report also analyzes factors (such as drivers, restraints and opportunities) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total regenerative medicine market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on regenerative medicines offered by the top 10 players in the regenerative medicine market. The report analyzes the regenerative medicine market by type, application, and region

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various regenerative medicine across key geographic regions.

• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the regenerative medicine market

• Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the regenerative medicine market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.2.1 MARKETS COVERED 14
1.2.2 YEARS CONSIDERED FOR THE STUDY 14
1.3 CURRENCY 15
1.4 LIMITATIONS 15
1.5 STAKEHOLDERS 15
2 RESEARCH METHODOLOGY 16
2.1 SECONDARY DATA 17
2.1.1 KEY DATA FROM SECONDARY SOURCES 17
2.2 PRIMARY DATA 18
2.2.1 KEY DATA FROM PRIMARY SOURCES 19
2.3 MARKET SIZE ESTIMATION 19
2.3.1 BOTTOM-UP APPROACH 20
2.3.2 TOP-DOWN APPROACH 20
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 21
2.5 ASSUMPTIONS FOR THE STUDY 22
3 EXECUTIVE SUMMARY 23
4 PREMIUM INSIGHTS 26
4.1 REGENERATIVE MEDICINE: MARKET OVERVIEW 26
4.2 REGENERATIVE MEDICINE MARKET, BY TYPE & APPLICATION (2019) 27
4.3 GEOGRAPHICAL SNAPSHOT OF THE REGENERATIVE MEDICINE MARKET 28
5 MARKET OVERVIEW 29
5.1 INTRODUCTION 29
5.2 CLINICAL TRIALS FOR REGENERATIVE MEDICINE 29
5.3 MARKET DYNAMICS 30
5.3.1 DRIVERS 31
5.3.1.1 Rising prevalence of chronic diseases and genetic disorders 31
5.3.1.2 Rising government investments in regenerative medicine research 32
5.3.1.3 Product approvals and growing pipeline of regenerative medicine products 33

5.3.2 RESTRAINTS 34
5.3.2.1 Ethical concerns related to the use of embryonic stem cells in Research & Development 34
5.3.3 OPPORTUNITIES 34
5.3.3.1 Implementation of the 21st century cures act 34
5.3.3.2 Rising demand for organ transplantation 34
6 REGENERATIVE MEDICINE MARKET, BY TYPE 35
6.1 INTRODUCTION 36
6.2 CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS 37
6.2.1 ALLOGENEIC PRODUCTS 39
6.2.2 AUTOLOGOUS PRODUCTS 40
6.3 TISSUE-ENGINEERED PRODUCTS 41
6.4 GENE THERAPY PRODUCTS 42
7 REGENERATIVE MEDICINE MARKET, BY APPLICATION 43
7.1 INTRODUCTION 44
7.2 MUSCULOSKELETAL DISORDERS 45
7.2.1 MUSCULOSKELETAL DISORDERS SEGMENT WILL CONTINUE TO DOMINATE THE REGENERATIVE MEDICINE MARKET IN 2024 45
7.3 WOUND CARE 46
7.3.1 INCREASING PREVALENCE OF TARGET CONDITIONS TO DRIVE THE GROWTH OF THIS APPLICATION SEGMENT 46
7.4 ONCOLOGY 47
7.4.1 INCREASING PREVALENCE OF CANCER TO SUPPORT MARKET GROWTH 47
7.5 OCULAR DISORDERS 49
7.5.1 GROWING NUMBER OF PRODUCT APPROVALS TO SUPPORT MARKET GROWTH 49
7.6 DIABETES 50
7.6.1 INCREASING INCIDENCE OF DIABETES AND THE GROWING FOCUS OF COMPANIES ON DEVELOPING REGENERATIVE MEDICINE FOR THE TREATMENT OF DIABETES ARE THE KEY FACTORS DRIVING MARKET GROWTH 50
7.7 OTHER APPLICATIONS 51
8 REGENERATIVE MEDICINE MARKET, BY REGION 52
8.1 INTRODUCTION 53
8.2 NORTH AMERICA 54
8.2.1 US 57
8.2.1.1 US accounts for the largest share of the regenerative medicine market in North America 57
8.2.2 CANADA 60
8.2.2.1 Increasing R&D funding for regenerative medicine is a key factor influencing the growth of the Canadian regenerative medicine market 60

8.3 EUROPE 61
8.3.1 UK 63
8.3.1.1 UK accounts for the largest market share in the European market 63
8.3.2 GERMANY 64
8.3.2.1 Germany has a strong foundation for R&D, including over 1,000 public and private institutions 64
8.3.3 FRANCE 66
8.3.3.1 Rising R&D expenditure, a major growth driver in France 66
8.3.4 REST OF EUROPE 67
8.4 ASIA PACIFIC 69
8.4.1 JAPAN 70
8.4.1.1 Comparatively lenient regulations and rising geriatric population will drive market growth 70
8.4.2 CHINA 72
8.4.2.1 Favorable investments and government support will contribute to the growth of the Chinese market 72
8.4.3 AUSTRALIA 74
8.4.3.1 Strong research base and availability of funds will push market growth in Australia 74
8.4.4 ROAPAC 75
8.5 REST OF THE WORLD 77
9 COMPETITIVE LANDSCAPE 79
9.1 OVERVIEW 79
9.2 MARKET RANKING ANALYSIS, 2017 80
9.3 KEY STRATEGIES 81
9.3.1 PRODUCT LAUNCHES 81
9.4 COMPETITIVE LEADERSHIP MAPPING (2018) 82
9.4.1 VENDOR INCLUSION CRITERIA 82
9.4.2 VISIONARY LEADERS 82
9.4.3 INNOVATORS 82
9.4.4 DYNAMIC DIFFERENTIATORS 82
9.4.5 EMERGING COMPANIES 83
9.5 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2018) 84
9.5.1 PROGRESSIVE COMPANIES 84
9.5.2 STARTING BLOCKS 84
9.5.3 RESPONSIVE COMPANIES 84
9.5.4 DYNAMIC COMPANIES 84

10 COMPANY PROFILES 86
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
10.1 NOVARTIS AG 86
10.2 VERICEL 88
10.3 INTEGRA LIFESCIENCES 90
10.4 MIMEDX GROUP 92
10.5 STRYKER 94
10.6 WRIGHT MEDICAL 96
10.7 SPARK THERAPEUTICS 98
10.8 OSIRIS THERAPEUTICS 99
10.9 KITE PHARMA (SUBSIDIARY OF GILEAD SCIENCES) 101
10.10 ORGANOGENESIS 102

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
11 APPENDIX 103
11.1 INSIGHTS FROM INDUSTRY EXPERTS 103
11.2 DISCUSSION GUIDE 104
11.3 AVAILABLE CUSTOMIZATIONS 106
11.4 RELATED REPORTS 106
11.5 AUTHOR DETAILS 107

LIST OF TABLES

TABLE 1 FEW IMPORTANT CLINICAL STUDIES IN THE REGENERATIVE MEDICINE MARKET 29
TABLE 2 CANCER INCIDENCE AND MORTALITY, BY REGION, 2012–2035 31
TABLE 3 FUNDING FOR REGENERATIVE MEDICINE RESEARCH
BY THE NIH UNDER THE 21ST CENTURY CURES ACT 32
TABLE 4 NIH FUNDING FOR REGENERATIVE MEDICINE RESEARCH IN THE US,
2014–2016 (USD MILLION) 32
TABLE 5 CALIFORNIA INSTITUTE OF REGENERATIVE MEDICINE FUNDING FOR REGENERATIVE MEDICINE RESEARCH 33
TABLE 6 NUMBER OF COMPANIES OPERATING IN THE REGENERATIVE MEDICINE MARKET, BY REGION (2014–2018) 33
TABLE 7 REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION) 36
TABLE 8 FEW OF THE COMMERCIALIZED CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS 37
TABLE 9 CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY REGION, 2017–2024 (USD BILLION) 38
TABLE 10 CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 39
TABLE 11 CELL-BASED ALLOGENEIC REGENERATIVE MEDICINE 39
TABLE 12 ALLOGENEIC PRODUCTS MARKET, BY REGION, 2017–2024 (USD BILLION) 39
TABLE 13 CELL-BASED AUTOLOGOUS REGENERATIVE MEDICINE 40
TABLE 14 AUTOLOGOUS PRODUCTS MARKET, BY REGION, 2017–2024 (USD BILLION) 40
TABLE 15 FEW OF THE COMMERCIALIZED TISSUE-ENGINEERED PRODUCTS 41
TABLE 16 REGENERATIVE MEDICINE MARKET FOR TISSUE-ENGINEERED PRODUCTS,
BY REGION, 2017–2024 (USD BILLION) 41
TABLE 17 FEW OF THE COMMERCIALIZED GENE THERAPY PRODUCTS 42
TABLE 18 REGENERATIVE MEDICINE MARKET FOR GENE THERAPY PRODUCTS,
BY REGION, 2017–2024 (USD BILLION) 42
TABLE 19 REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2017–2024 (USD BILLION) 44
TABLE 20 REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS,
BY REGION, 2017–2024 (USD BILLION) 45
TABLE 21 REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR THE TREATMENT OF ACUTE & CHRONIC WOUNDS 46
TABLE 22 REGENERATIVE MEDICINE MARKET FOR WOUND CARE, BY REGION,
2017–2024 (USD BILLION) 46
TABLE 23 NUMBER OF CANCER PATIENTS, BY TYPE, 2012–2030 47
TABLE 24 INDICATIVE LIST OF COMMERCIALIZED REGENERATIVE CELL-BASED IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER 48
TABLE 25 REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION,
2017–2024 (USD BILLION) 49
TABLE 26 REGENERATIVE MEDICINE MARKET FOR OCULAR DISORDERS,
BY REGION, 2017–2024 (USD BILLION) 49
TABLE 27 REGENERATIVE MEDICINE MARKET FOR DIABETES, BY REGION,
2017–2024 (USD BILLION) 50
TABLE 28 REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS,
BY REGION, 2017–2024 (USD BILLION) 51
TABLE 29 REGENERATIVE MEDICINE MARKET, BY REGION, 2017–2024 (USD BILLION) 53
TABLE 30 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY,
2017–2024 (USD BILLION) 56
TABLE 31 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY TYPE,
2017–2024 (USD BILLION) 56
TABLE 32 NORTH AMERICA: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017–2024 (USD BILLION) 56
TABLE 33 NORTH AMERICA: REGENERATIVE MEDICINE, BY APPLICATION,
2017–2024 (USD BILLION) 57
TABLE 34 PRODUCTS WITH RMAT DESIGNATION (AS OF 2018) 58
TABLE 35 US: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION) 59
TABLE 36 US: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 59
TABLE 37 US: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION) 59
TABLE 38 CANADA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION) 60
TABLE 39 CANADA: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 60
TABLE 40 CANADA: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION) 61
TABLE 41 RESEARCH FUNDING EUROPEAN OVERVIEW 61
TABLE 42 EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY,
2017–2024 (USD BILLION) 62
TABLE 43 EUROPE: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION) 62
TABLE 44 EUROPE: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 62
TABLE 45 EUROPE: REGENERATIVE MEDICINE, BY APPLICATION, 2017–2024 (USD BILLION) 63
TABLE 46 UK: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION) 63
TABLE 47 UK: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 64
TABLE 48 UK: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION) 64
TABLE 49 GERMANY: REGENERATIVE MEDICINE MARKET, BY TYPE,
2017–2024 (USD BILLION) 65
TABLE 50 GERMANY: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017–2024 (USD BILLION) 65
TABLE 51 GERMANY: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION) 65
TABLE 52 FRANCE: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION) 66
TABLE 53 FRANCE: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 66
TABLE 54 FRANCE: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION) 67
TABLE 55 ROE: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION) 68
TABLE 56 ROE: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 68
TABLE 57 ROE: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION) 68
TABLE 58 APAC: REGENERATIVE MEDICINE MARKET, BY COUNTRY,
2017–2024 (USD BILLION) 69
TABLE 59 APAC: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION) 69
TABLE 60 APAC: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 70
TABLE 61 APAC: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION) 70
TABLE 62 JAPAN: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION) 71
TABLE 63 JAPAN: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 71
TABLE 64 JAPAN: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION) 72
TABLE 65 CHINA: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION) 72
TABLE 66 CHINA: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 73
TABLE 67 CHINA: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION) 73
TABLE 68 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY TYPE,
2017–2024 (USD BILLION) 74
TABLE 69 AUSTRALIA: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET, BY TYPE, 2017–2024 (USD BILLION) 74
TABLE 70 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION) 75
TABLE 71 ROAPAC: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION) 75
TABLE 72 ROAPAC: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 76
TABLE 73 ROAPAC: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION) 76
TABLE 74 ROW: REGENERATIVE MEDICINE MARKET, BY TYPE, 2017–2024 (USD BILLION) 77
TABLE 75 ROW: CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS MARKET,
BY TYPE, 2017–2024 (USD BILLION) 77
TABLE 76 ROW: REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2017–2024 (USD BILLION) 78


LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN 16
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 18
FIGURE 3 REGENERATIVE MEDICINE MARKET: BOTTOM-UP APPROACH 20
FIGURE 4 REGENERATIVE MEDICINE MARKET: TOP-DOWN APPROACH 20
FIGURE 5 DATA TRIANGULATION METHODOLOGY 21
FIGURE 6 REGENERATIVE MEDICINE MARKET, BY TYPE, 2019 VS. 2024 (USD BILLION) 23
FIGURE 7 REGENERATIVE MEDICINE MARKET, BY APPLICATION,
2019 VS. 2024 (USD BILLION) 24
FIGURE 8 REGENERATIVE MEDICINE MARKET, BY REGION, 2019 VS. 2024 (USD BILLION) 24
FIGURE 9 GROWING GOVERNMENT INVESTMENTS IN REGENERATIVE MEDICINE RESEARCH TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD 26
FIGURE 10 MUSCULOSKELETAL DISORDERS TO DOMINATE THE REGENERATIVE MEDICINE MARKET IN 2019 27
FIGURE 11 COUNTRIES IN EUROPE TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD 28
FIGURE 12 REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 30
FIGURE 13 CELL-BASED IMMUNOTHERAPY & CELL THERAPY PRODUCTS SEGMENT TO DOMINATE THE MARKET IN 2018 36
FIGURE 14 ONCOLOGY SEGMENT TO REGISTER THE HIGHEST GROWTH IN THE REGENERATIVE MEDICINE MARKET DURING THE FORECAST PERIOD 44
FIGURE 15 PREVALENCE OF DIABETES, BY REGION, 2015 VS. 2040 50
FIGURE 16 NORTH AMERICA TO WITNESS THE HIGHEST GROWTH IN THE REGENERATIVE MEDICINE MARKET DURING THE FORECAST PERIOD 53
FIGURE 17 INVESTMENT LEVELS QUADRUPLED DURING 2010–2016 54
FIGURE 18 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT 55
FIGURE 19 KEY DEVELOPMENTS IN THE REGENERATIVE MEDICINE MARKET 79
FIGURE 20 REGENERATIVE MEDICINE MARKET RANKING, BY KEY PLAYER, 2018 80
FIGURE 21 MNM DIVE-VENDOR COMPARISON MATRIX: REGENERATIVE MEDICINE MARKET 83
FIGURE 22 MNM DIVE-VENDOR COMPARISON MATRIX FOR START-UPS: REGENERATIVE MEDICINE MARKET 85
FIGURE 23 NOVARTIS: COMPANY SNAPSHOT 86
FIGURE 24 VERICEL: COMPANY SNAPSHOT 88
FIGURE 25 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT 90
FIGURE 26 MIMEDX GROUP: COMPANY SNAPSHOT 92
FIGURE 27 STRYKER : COMPANY SNAPSHOT 94
FIGURE 28 WRIGHT MEDICAL: COMPANY SNAPSHOT 96
FIGURE 29 OSIRIS THERAPEUTICS: COMPANY SNAPSHOT 99


【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[再生医療の世界市場予測(~2024年)]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆